On December 16, 2024, GSK plc announced that the US FDA granted Breakthrough Therapy Designation for Jemperli (dostarlimab) to treat locally advanced dMMR/MSI-H rectal cancer, based on a clinical trial showing a 100% complete response rate in 42 patients.